Article Sidebar

PDF
Date Published: 28/02/2023
Abstract Views: 67
Views PDF: 72
DOI: https://doi.org/10.56535/jmpm.v48i2.251
Issue
Vol. 48 No. 2 (2023): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 2 - 2023
Section
Articles
How to Cite
Nguyễn, N. Á., Cấn , V. M., & Lê, V. T. (2023). RESEARCH ON PLASMA ERYTHROPOIETIN CONCENTRATION IN TYPE 2 DIABETIC PATIENTS WITH KIDNEY INJURY. Journal of Military Pharmaco-medicine, 48(2), 64-72. https://doi.org/10.56535/jmpm.v48i2.251

RESEARCH ON PLASMA ERYTHROPOIETIN CONCENTRATION IN TYPE 2 DIABETIC PATIENTS WITH KIDNEY INJURY

Nguyen Ngoc Anh1, , Cấn Văn Mão2, Lê Việt Thắng2
1 Hai Phong University of Medicine and Pharmacy
2 Vietnam Military Medical University

Main Article Content

Abstract

Objectives: To investigate plasma erythropoietin (EPO) concentration and its relationship with some characteristics in type 2 diabetic patients (T2DM) with chronic kidney injury (CKI). Subjects and methods: A cross-sectional descriptive study on 219 subjects, including 129 patients with type 2 diabetes with chronic kidney injury, 51 patients with diabetes without CKI as a disease control group, and 39 healthy people as a normal control group. All subjects had their plasma EPO levels quantified by ELISA. Results: The median EPO concentration of the research group was 35.83 (21.55 - 56.34) UI/L, lower than the disease control group, which was 44.72 (37.25 - 63.90) UI/L, and lower than the normal control group, which was 113.31 (30.55 - 378.42) UI/L, p < 0.001. The rate of EPO reduction in the study group was 41.9%. EPO concentration was positively correlated with GFR, r = 0.242, p < 0.01. Creatinine is an independent factor associated with reduced EPO, p < 0.05. Conclusion: The rate of EPO reduction in the type 2 DM group with CKI was 41.9%. Decreases in EPO levels are common in KI patients with type 2 diabetes and are associated with decreased GFR.

Article Details

Keywords

Type 2 diabetes Mellitus, Renal Injury, GFR, Plasma EPO levels

References

1. Andrews M., Arredondo M. (2012). Ferritin levels and hepcidin mRNA expression in peripheral mononuclear cells from anemic type 2 diabetic patients. Biological Trace Element Research; 149(1):1-4.
2. Barbieri J., Fontela P.C., Winkelmann E.R., et al. (2015). Anemia in Patients with Type 2 Diabetes Mellitus. Anemia; 2015:354737.
3. Deray G., Heurtier A., Grimaldi A., et al. (2004). Anemia and diabetes. Am J Nephrol; 24(5):522-526.
4. Panjeta M., Tahirović I., Sofić E., et al. (2017). Interpretation of Erythropoietin and Haemoglobin Levels in Patients with Various Stages of Chronic Kidney Disease. J Med Biochem; 36(2):145-152.
5. Fujita Y., Doi Y., Hamano T., et al. (2019). Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: A prospective cohort study. Sci Rep; 9(1):14871.
6. Symeonidis A., Kouraklis-Symeonidis A., Psiroyiannis A., et al. (2006). Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus. Annals of hematology; 85:79-85.
7. Jelkmann W. (2011). Regulation of erythropoietin production. J Physiol; 589(6):1251-1258.
8. Pappa M., Dounousi E., Duni A., et al. (2015). Less known pathophysiological mechanisms of anemia in patients with diabetic nephropathy. Int Urol Nephrol; 47(8):1365-1372.